I am not sure at all Nemesis that NICE will consider the cost
of DCVax-L to be insurmountable because I am speculating
that the DCVax-L treatment, while it may include the additional cost
of poly ICLC, will soon not include the much more expensive agent,
temozolamide.
Also with any luck, an increasing proportion of GBM patients may survive
and will not incur the long term expenses of severely ill patients who
while they are still alive, need constant care that can end up being
an additional burden for the NHS.
Bullish
Market Data 
Markets 
AI
